Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP cut its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 54.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,977 shares of the company’s stock after selling 66,845 shares during the quarter. Quantbot Technologies LP’s holdings in Teva Pharmaceutical Industries were worth $967,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth $106,000. Kistler Tiffany Companies LLC grew its holdings in Teva Pharmaceutical Industries by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its holdings in Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $129,000. Finally, Cutler Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $133,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up $0.68 on Thursday, hitting $15.00. 15,847,280 shares of the stock traded hands, compared to its average volume of 15,675,079. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $15,600.00, a P/E ratio of 3.48 and a beta of 0.55. Teva Pharmaceutical Industries Limited has a 1-year low of $10.85 and a 1-year high of $38.31.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.27%. The ex-dividend date is Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is presently -12.27%.

Several brokerages have issued reports on TEVA. BidaskClub cut shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Citigroup cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Credit Suisse Group restated an “outperform” rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, September 11th. Finally, Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus target price of $21.65.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2017/12/07/quantbot-technologies-lp-sells-66845-shares-of-teva-pharmaceutical-industries-limited-teva-updated-updated.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply